Aquestive Therapeutics Files 8-K

Ticker: AQST · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1398733

Aquestive Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAquestive Therapeutics, Inc. (AQST)
Form Type8-K
Filed DateSep 8, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: AQST

TL;DR

AQST filed a standard 8-K, no new news.

AI Summary

Aquestive Therapeutics, Inc. filed an 8-K on September 8, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.

Why It Matters

This filing indicates Aquestive Therapeutics is fulfilling its regulatory reporting obligations with the SEC. It does not disclose new material information that would immediately impact the company's stock price.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for regulatory compliance and does not contain any new material events or financial disclosures.

Key Players & Entities

  • Aquestive Therapeutics, Inc. (company) — Registrant
  • September 8, 2025 (date) — Date of Report
  • 30 Technology Drive Warren, NJ 07059 (location) — Principal Executive Offices
  • MonoSol Rx, Inc. (company) — Former Company Name

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report information under Regulation FD and to file financial statements and exhibits, as indicated in the filing.

When was this 8-K report filed?

This 8-K report was filed on September 8, 2025.

What is the principal executive office address for Aquestive Therapeutics, Inc.?

The principal executive office address for Aquestive Therapeutics, Inc. is 30 Technology Drive, Warren, NJ 07059.

Has Aquestive Therapeutics, Inc. had a former company name?

Yes, Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx, Inc., with a date of name change on May 7, 2007.

What is the state of incorporation for Aquestive Therapeutics, Inc.?

Aquestive Therapeutics, Inc. is incorporated in Delaware.

Filing Stats: 606 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-09-08 08:32:00

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I

Filing Documents

01

Item 7.01 Regulation FD Disclosure Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others. This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's investor presentation given to investors, analysts and others at the H.C. Wainwright 27th Annual Global Investor Conference on September 8, 2025 is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The H.C. Wainwright presentation is available on the Company's website located at www.aquestive.com, although the Company reserves the right to discontinue that availability at any time. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Aquestive Therapeutics, Inc. H.C. Wainwright 27th Annual Global Investor Conference Presentation dated September 8, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 8, 2025 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.